As we slowly emerged from our COVID caves of 2020-2021, this year brought great excitement to Medlior. We helped industry bring life-changing innovations to market, and we increased our stakeholder collaboration.
Category
Insights
Men’s Mental Health: A Silent Crisis
November is men’s health awareness month – and some of the less-often-talked about health issues affecting men are about their mental health. The Canadian Mental Health Association is calling this a “silent crisis, a sleeper issue”.
CADTH RWE Framework
I had the pleasure of attending the The Canadian Association for Population Therapeutics annual conference in Toronto, Canada. The program was titled “Embracing Change and Uncertainty to Improve the Health of Canadians” and it was kicked-off with a townhall session on Canadian RWE Initiatives…
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Presentations: Trends in Osteoporotic Incidences and Care during the COVID-19 Pandemic
A real-world evidence study examining COVID-19 pandemic disruptions in osteoporosis care patterns and outcomes across Alberta, Canada, was presented through two posters at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Early Diagnosis of Alzheimer’s Disease Using AI Techniques in Primary Care
Alzheimer’s disease (AD) is a degenerative neurological disease with progressive death of brain cells, eventually leading to death.1,2 It is the most prevalent irreversible dementia, marked by deterioration of memory, judgement, and reasoning and worsening of mood, behaviour, communication, and function to perform daily activities.1 With longer life expectancy and an aging population, the burden of AD on the quality of life of patients and their family and caregivers is increasing.
Indigenous healthcare research in Canada—A changing landscape
With National Indigenous People’s Day on June 21st, Medlior is reflecting on health disparities for Indigenous peoples in Canada. First Nations, Inuit, and Métis people have typically been underrepresented in research studies, but there are promising signs of change.
Canada’s Rare Disease Strategy – What is it and why do we care?
Approximately 1 in 12 Canadians, mostly children, are affected by a rare disorder. Patients with rare diseases face many challenges, including misdiagnosis, limited treatment, and difficulty accessing innovative therapies even when they are available. Implementing the Rare Disease Strategy will not necessarily cost Canadians more. Earlier diagnosis and correct treatments can lead to reduced unnecessary surgeries, organ transplants, and visits to multiple specialists, resulting in savings for the health system and taxpayers.
Value-based Health Care
Reflecting over the last 2 years The pandemic has shown us the crucial imperative of having highly functioning and interconnected healthcare systems. Everything comes at a cost which is why it is so important to achieve the greatest value for money. But what is value...
Looking Forward To 2022
Following the unprecedented year of 2020, 2021 brought increased global awareness to our field of work. The pandemic has brought terms such as ‘epidemiology’, ‘efficacy’ and ‘real word evidence’ into lay language and the vital role of health outcomes research has...
Looking Back On 2021
As the reality of living amongst a global pandemic set in across the world over the past year, a key highlight of 2021 was undoubtedly the rollout of life saving vaccines from AstraZeneca, Pfizer, Johnson and Johnson, and Moderna. At Medlior, this was also a year of...
